关键词：HER-2；人类表皮生长因子；癌基因；激进类型；乳腺癌；传播和转移；速度
摘 要：HER-2 is a member of the human EGFR family. Overexpression or amplification of this oncogene has been linked to certain aggressive types of breast cancer. HER-2 positive breast cancers have a tendency to spread and metastasize more rapidly than other forms of cancers. They also tend to affect women more than men. The GLOBOCAN project reported that, in 2012, breast cancer accounted for 11.90 percent of the total cancer cases and led to 522,000 deaths worldwide. HER-2 positive breast cancer accounts for almost 25.00 percent of all types of breast cancer.
目 录：

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

03.1 Market Overview

03.2 Product Offerings

04. Market Research Methodology

04.1 Market Research Process

04.2 Research Methodology

05. Introduction

06. Disease Overview

06.1 Understanding the Disease

06.2 Pathophysiology

06.3 Epidemiology

06.4 Diagnosis

06.4.1 IHC

06.4.2 FISH

06.4.3 SPoT-Light HER-2 CISH Test (Subtraction Probe Technology

Chromogenic In Situ Hybridization)

06.4.4 Inform HER-2 Dual ISH Test (Inform Dual In Situ

Hybridization)

06.5 Management

06.5.1 Surgery

06.5.2 Radiotherapy

06.5.3 Chemotherapy

06.5.4 Targeted Therapy

06.5.5 Hormonal Therapy

06.6 Economic Burden

07. Market Landscape

07.1 Market Overview

07.2 Market Size and Forecast

07.3 Five Forces Analysis

08. Market Segmentation by Type of Therapy

08.1 Chemotherapy

08.1.1 Alkylating Agents

08.1.2 Antimetabolites

08.1.3 Cytotoxic Antibiotics

08.1.4 Taxanes

08.2 Targeted Therapy

08.3 Hormone Therapy

09. Market Segmentation by Molecule Type

09.1 Biologics

09.2 Small Molecules

10. Market Segmentation by Route of

Administration

10.1 Oral

10.2 Parenteral

11. Buying Criteria

12. Market Growth Drivers

13. Drivers and their Impact

14. Market Challenges

15. Impact of Drivers and Challenges

16. Market Trends

17. Trends and their Impact

18. Vendor Landscape

18.1 Competitive Scenario

18.1.1 Key News

18.1.2 Mergers and Acquisitions

18.2 Market Share Analysis 2014

18.2.1 Competitive Assessment of the Top Drugs

18.2.2 Celgene

18.2.3 F. Hoffmann-La Roche

18.2.4 GlaxoSmithKline

18.2.5 Novartis

18.2.6 Sanofi

18.3 Other Prominent Vendors

19. Key Vendor Analysis

19.1 Celgene

19.1.1 Key Facts

19.1.2 Business Overview

19.1.3 Business Strategy

19.1.4 Business Segmentation by Revenue

19.1.5 Sales by Geography

19.1.6 Key Information

19.1.7 SWOT Analysis

19.2 F. Hoffmann-La Roche

19.2.1 Key Facts

19.2.2 Business Overview

19.2.3 Business Segmentation

19.2.4 Business Segmentation by Revenue 2012 and 2013

19.2.5 Sales by Geography

19.2.6 Business Strategy

19.2.7 Key Information

19.2.8 SWOT Analysis

19.3 GlaxoSmithKline

19.3.1 Key Facts

19.3.2 Business Overview

19.3.3 Business Segmentation

19.3.4 Business Segmentation by Revenue 2012 and 2013

19.3.5 Sales by Geography

19.3.6 Pipeline Products

19.3.7 Business Strategy

19.3.8 Key Information

19.3.9 SWOT Analysis

19.4 Novartis

19.4.1 Key Facts

19.4.2 Business Description1

19.4.3 Business Segmentation

19.4.4 Revenue by Business Segmentation

19.4.5 Revenue Comparison 2012 and 2013

19.4.6 Sales by Geography

19.4.7 Business Strategy

19.4.8 Key Developments

19.4.9 SWOT Analysis

19.5 Sanofi

19.5.1 Key Facts

19.5.2 Business Description

19.5.3 Business Segmentation

19.5.4 Revenue by Business Segmentation

19.5.5 Revenue Comparison 2012 and 2013

19.5.6 Sales by Geography

19.5.7 Business Strategy

19.5.8 Key Developments

19.5.9 SWOT Analysis

20. Other Reports in this Series